Piton Therapeutics key facts
as of Oct 2026- Developer of precision therapeutics designed for inflammatory, neurological, and metabolic diseases.
- Piton Therapeutics is valued at approximately $65.5M as of Oct 2026 (last reported valuation).
- It has raised $15.3M; the latest was Later Stage VC ($7.0M) in Dec 2024.
- Notable investors include Plum Ventures, K2VC, Future Capital Discovery Fund, Prescience Point Capital Management, ABI LAB — 8 tracked in total.
- Status: Privately Held (backing).
Piton Therapeutics's last reported valuation, Oct 2020. Nothing priced has surfaced since.
- ·Watch Piton Therapeutics: the Monday email on marks, rounds and moves
Piton Therapeutics funding rounds
No funding rounds for Piton Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Piton Therapeutics valuation
Piton Therapeutics's last reported valuation was $65.5 million in Oct 2020. No priced round, secondary trade or fund mark has surfaced since.
Piton Therapeutics investors
8 investors are on record for Piton Therapeutics, including Plum Ventures, K2VC, Future Capital Discovery Fund and Prescience Point Capital Management.
About Piton Therapeutics
Developer of precision therapeutics designed for inflammatory, neurological, and metabolic diseases. The company offers small-molecule drugs that modulate the gut microbiome's role in chronic conditions, enabling patients with disorders like Ulcerative Colitis, Type 2 Diabetes, Autism Spectrum Disorder, and Parkinson's Disease to access targeted and disease-modifying treatments.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2016
- Employees
- 12
- Website
- pitontx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.